CLSI M100 : Ed28E: 2018

Abstract
Committee Membership
Overview of Changes
Summary of CLSI Processes for Establishing
Breakpoints and Quality Control Ranges
CLSI Reference Methods vs Commercial Methods and
CLSI vs US Food and Drug Administration Breakpoints
CLSI Breakpoint Additions/Revisions Since 2010
CLSI Epidemiological Cutoff Value Additions/Revisions
Since 2015
CLSI Archived Resources
Subcommittee on Antimicrobial Susceptibility Testing
Mission Statement
Instructions for Use of Tables
References
Appendix A - Suggestions for Confirming Resistant,
Intermediate, or Nonsusceptible Antimicrobial
Susceptibility Test Results and Organism Identification
Appendix B - Intrinsic Resistance
Appendix C - QC Strains for Antimicrobial Susceptibility
             Tests
Appendix D - Cumulative Antimicrobial Susceptibility Report
             for Anaerobic Organisms
Appendix E - Dosage Regimens Used to Establish Susceptible
             or Susceptible-Dose Dependent Breakpoints
Appendix F - Cefepime Breakpoint Change for Enterobacteriaceae
             and Introduction of the Susceptible-Dose Dependent
             Interpretive Category
Appendix G - Epidemiological Cutoff Values
Glossary I (Part 1) - Beta-Lactams: Class and Subclass Designations
                      and Generic Name
Glossary I (Part 2) - Non-Beta-Lactams: Class and Subclass Designations
                      and Generic Name
Glossary II - Antimicrobial Agent Abbreviation(s), Route(s) of
              Administration, and Drug Class
Glossary III - List of Identical Abbreviations Used for
               More Than One Antimicrobial Agent in US
               Diagnostic Products
The Quality Management System Approach
Related CLSI Reference Materials